Adrian ML, et al. - In a real-life setting, authors evaluated the mean change in visual acuity (VA) overall and stratified by baseline VA after 1 and 2 years’ treatment with aflibercept. Researchers used nationwide data from the Swedish Macula Register. While eyes with poor baseline VA had a particularly pronounced gain in vision, good baseline VA was central for best prognosis. Among eyes with intermediate baseline VA, those treated according to label vs not according to label at 3, 6 and 12 months had significantly better near vision. They noted stability or improvement at 2 years in VA in 75% of treated eyes.